Payment overview · 2025
General Payments
$1,200.40
57 reported records · 21 companies
Healthcare provider profile · identity verified
Deepak T Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · SEBRING, FL · NPI 1821038852
Verified facts
What the public records show
CMS Open Payments records show Deepak T Patel, MD received $1,200.40 in general payments during 2025 across 57 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arikayce, Glassia.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 309 claims for Trelegy Ellipta by this doctor in 2024.
Insmed, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Arikayce as an associated drug or biological on 32500 records involving 8305 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Arikayce by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GLASSIA as an associated drug or biological on 7881 records involving 3215 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Glassia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $192.10 | 16.0% | 12 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $183.43 | 15.3% | 7 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $163.85 | 13.7% | 7 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $100.54 | 8.4% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $85.23 | 7.1% | 3 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $70.80 | 5.9% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $53.57 | 4.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.16 | 4.0% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $40.01 | 3.3% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.24 | 2.9% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $25.72 | 2.1% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $25.54 | 2.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.26 | 2.1% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $25.00 | 2.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.87 | 2.0% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $21.05 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.58 | 1.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.70 | 1.5% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $16.62 | 1.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.56 | 1.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.57 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,183.02 | 56 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $166.05 | 6 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $163.85 | 7 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $146.96 | 10 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $100.54 | 4 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $70.80 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $65.73 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $53.57 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $45.14 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $34.24 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $32.31 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $29.32 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $25.54 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Arikayce arikayce |
2025 | Arikayce | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GLASSIA glassia |
2025 | Glassia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
309 | 70 |
| Insmed, Inc. Exact reporting entity; no affiliate inference |
2025 | Arikayce open payments reported associated product |
CMS Open Payments — General Payments 32500 supporting records · 8305 recipient NPIs · example record 1186254431 |
Arikayce · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GLASSIA open payments reported associated product |
CMS Open Payments — General Payments 7881 supporting records · 3215 recipient NPIs · example record 1223616286 |
Glassia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 403 | 113 |
| Prednisone | Prednisone | 383 | 156 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 309 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 239 | 85 |
| Azithromycin | Azithromycin | 168 | 113 |
| Potassium Chloride | Potassium Chloride | 161 | 47 |
| Famotidine | Famotidine | 151 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 150 | 67 |
| Furosemide | Furosemide | 150 | 50 |
| Gabapentin | Gabapentin | 132 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 113 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 113 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 30 |
| Losartan Potassium | Losartan Potassium | 111 | 35 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 109 | 29 |
| Amoxicillin | Amoxicillin | 103 | 69 |
| Gentamicin Sulfate | Gentamicin Sulfate | 103 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 33 |
| Atorvastatin Calcium | Atorvastatin Calcium | 95 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 37 |
| Metformin Hcl | Metformin Hcl | 93 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 92 | 46 |
| Ventolin Hfa | Albuterol Sulfate | 91 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 74 |
| Levofloxacin | Levofloxacin | 85 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 20 |
| Xarelto | Rivaroxaban | 74 | 20 |
| Pregabalin | Pregabalin | 73 | 17 |
| Omeprazole | Omeprazole | 72 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 19 |
| Eliquis | Apixaban | 70 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 18 |
| Lisinopril | Lisinopril | 70 | 21 |
| Alprazolam | Alprazolam | 68 | 16 |
| Methylprednisolone | Methylprednisolone | 68 | 56 |
| Tramadol Hcl | Tramadol Hcl | 68 | 19 |
| Simvastatin | Simvastatin | 66 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 65 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 65 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 53 | suppressed |
| Ozempic | Semaglutide | 52 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | 12 |
| Buspirone Hcl | Buspirone Hcl | 50 | 11 |
| Meropenem | Meropenem | 49 | 14 |
| Allopurinol | Allopurinol | 47 | 11 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 33 |
| Clonidine Hcl | Clonidine Hcl | 45 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 45 | 18 |
| Metformin Hcl Er | Metformin Hcl | 44 | 14 |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 42 | suppressed |
| Roflumilast | Roflumilast | 41 | suppressed |
| Bumetanide | Bumetanide | 40 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 39 | 21 |
| Mirtazapine | Mirtazapine | 38 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 37 | 11 |
| Ertapenem | Ertapenem Sodium | 36 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 20 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Meloxicam | Meloxicam | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | 14 |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 31 | suppressed |
| Carisoprodol | Carisoprodol | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 11 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 14 |
| Ofev | Nintedanib Esylate | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Belsomra | Suvorexant | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Daptomycin | Daptomycin | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Rifampin | Rifampin | 23 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Linezolid | Linezolid | 22 | 14 |
| Mupirocin | Mupirocin | 22 | 11 |
| Acthar | Corticotropin | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | 16 |
| Opsumit | Macitentan | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Dupixent Syringe | Dupilumab | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 15 |
| Clonazepam | Clonazepam | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Cefdinir | Cefdinir | 13 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 11 |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glassia | Alpha-1-Proteinase Inhibitor | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,200.40 · 57 records | Takeda Pharmaceuticals U.S.A., Inc. | Arikayce, CHARTIS CATHETER, DUPIXENT, FASENRA, GLASSIA, HYQVIA, Hillrom - Vest System Model 105 Home Care, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, KEYTRUDA, Kerecis GraftGuide, Kerecis SurgiClose, NUCALA, NUZYRA, ONPATTRO, Ohtuvayre, PULMONX CHARTIS TABLET CONSOLE, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, SMARTVEST, Sunosi, VOWST, WINREVAIR, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, ZERBAXA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arikayce play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error